Description of the Particular Matter to Which the Waiver Applies: The committee will discuss the clinical pharmacology aspects of pediatric clinical trial design and dosing to optimize pediatric drug development. FDA wi

First Page		Document Content
Pharmacokinetics Pharmacodynamics Clinical pharmacology Clinical trial Simulation Food and Drug Administration Drug development PK/PD models Pharmaceutical sciences Pharmacology Clinical research		Description of the Particular Matter to Which the Waiver Applies: The committee will discuss the clinical pharmacology aspects of pediatric clinical trial design and dosing to optimize pediatric drug development. FDA wi Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 252,15 KB Share Document on Facebook

	Announcing a Post-ACoP7 workshop presented by Simulation from ODE-based population PK/PD and systems pharmacology models in R using mrgsolve Register today at www.acop7.org DocID: 1mnJ0 - View Document
	Source-to-Outcome Modeling Physiologically Based Pharmacokinetic/Pharmacodynamic (PBPK/PD) Model Linked to a Dietary Exposure Model: Chlorpyrifos as a Case Study Science Issues Paper for SAP Meeting on Chlorpyrifos Physi DocID: 1fHeU - View Document
	PDF Document DocID: 17qM1 - View Document
	Exposure Response in Drug Development DocID: 13a39 - View Document
	An Introduction to Nonlinear Mixed Effects Models and PK/PD Analysis Marie Davidian Department of Statistics North Carolina State University DocID: 11UeQ - View Document